Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02378883 · ClinicalTrials.gov registry record · NA

Apollo™ Onyx™ Delivery Microcatheter Post Market Safety Study

A NA study, sponsored by Medtronic Neurovascular Clinical Affairs.

Completed
Registry status
NA
Development phase
112
Enrollment target

NCT02378883 is a NA study that has completed, run by Medtronic Neurovascular Clinical Affairs. The registered enrollment target is 112 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02378883, a NA study, has completed, sponsored by Medtronic Neurovascular Clinical Affairs.

COMPLETED
Registry status
NA
Development phase
112 participants
Enrollment target

Study Summary

The purpose of this study is to evaluate the safety of the Apollo™ Onyx™ Delivery Microcatheter used for delivery of the Onyx™ Liquid Embolic System during brain arteriovenous malformation (AVM) embolization procedures.

Interventions

  • DEVICE Apollo™ Onyx™ Delivery Micro Catheter

Trial Details

FieldValue
Enrollment Target 112 participants
Start Date 2015-05-18
Est. Completion 2018-02-20
Phase NA

What the Registry Record Tells You About NCT02378883

The ClinicalTrials.gov registry entry for NCT02378883 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 112 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medtronic Neurovascular Clinical Affairs, which has 20 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Apollo™ Onyx™ Delivery Micro Catheter is the first listed.

NCT02378883 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02378883 about?

NCT02378883 is a clinical study titled "Apollo™ Onyx™ Delivery Microcatheter Post Market Safety Study". The purpose of this study is to evaluate the safety of the Apollo™ Onyx™ Delivery Microcatheter used for delivery of the Onyx™ Liquid Embolic System during brain arteriovenous malformation (AVM) embolization procedures.

What is the current status of trial NCT02378883?

This trial is currently completed. It is a NA study. The enrollment target is 112 participants. The study started on 2015-05-18. Estimated completion is 2018-02-20.

What interventions are being tested in trial NCT02378883?

The interventions under investigation include: Apollo™ Onyx™ Delivery Micro Catheter (DEVICE).

Who is sponsoring clinical trial NCT02378883?

This trial is sponsored by Medtronic Neurovascular Clinical Affairs, which has 20 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.